# Romosozumab

## Evenity inj 105mg/1.17mL

| TAH Drug Code      | [IEVE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEVE                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.                                                                                                                                                        |
| Dosing             | Two separate syringes (and two separate subcutaneous injections) are needed to administer the total dose of 210 mg of Evenity. Inject two 105 mg/1.17 mL prefilled syringes, one after the other. Should be administered by a healthcare provider. Administer 210 mg subcutaneously once every month for 12 doses in the abdomen, thigh, or upper arm. Adequately supplement calcium and vitamin D during treatment. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypocalcemia. Known hypersensitivity to Evenity.                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common Musculoskeletal: Arthralgia (8.1% to 13.1% ) Neurologic: Headache (5.2% to 6.6% ) Serious Cardiovascular: Myocardial infarction (0.3% to 0.8% ) Endocrine metabolic: Hypocalcemia (0.04% ) Immunologic: Hypersensitivity reaction (6.5% ) Musculoskeletal: Femur shaft fracture (0.02% ), Osteonecrosis of jaw (0.02% ) Neurologic: Cerebrovascular accident (0.2% to 0.6% )                                  |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/romosozumab-drug-information)                                                                                                                                                                                                                                                                                                                                           |

